trial

Treating Refractory Schizophrenia With rTMS

NCTId NCT02242578
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 2 (actual)
Sponsored by Seton Healthcare Family
Primary completion 2018-06-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
2 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-01-24
Primary completion
2018-06-11
Eligibility
ALL · 18 Years · 80 Years

Interventions & indications

Drugs
1 Hz rTMS10 Hz rTMS

Sponsors

Seton Healthcare FamilyLead Sponsor
Abbott Medical DevicesCollaborator
University of Texas at AustinCollaborator

Investigators

1
Robert W Buchanan, MDPrincipal Investigator

Sites

1 total
Austin, United States

Facts & assertions

4 sourced
Enrollment
2
Phase
NA
Primary Completion Date
2018-06-11
Status
TERMINATED
relationships
The graph out of here
drug
1 Hz rTMS
drug
10 Hz rTMS
drug
lead_sponsor
Seton Healthcare Family
company
collaborator
Abbott Medical Devices
company
University of Texas at Austin
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Robert W Buchanan, MD
person